Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2013

01.06.2013 | Original Article

Attributes of brain metastases from breast and lung cancer

verfasst von: Kyle Hengel, Gurinder Sidhu, Jai Choi, Jeremy Weedon, Emmanuel Nwokedi, Constantine A. Axiotis, Xianyuan Song, Albert S. Braverman

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Most brain metastases arise from breast and lung cancers. Few studies compare the brain regions they involve, their numbers and intrinsic attributes.

Methods

Records of all patients referred to Radiation Oncology for treatment of symptomatic brain metastases were obtained. Computed tomography (n = 56) or magnetic resonance imaging (n = 72) brain scans were reviewed.

Results

Data from 68 breast and 62 lung cancer patients were compared. Brain metastases presented earlier in the course of the lung than of the breast cancer patients (p = 0.001). There were more metastases in the cerebral hemispheres of the breast than of the lung cancer patients (p = 0.014). More breast than lung cancer patients had cerebellar metastases (p = 0.001). The number of cerebral hemisphere metastases and presence of cerebellar metastases were positively correlated (p = 0.001). The prevalence of at least one metastasis surrounded with >2 cm of edema was greater for the lung than for the breast patients (p = 0.019). The primary tumor type, rather than the scanning method, correlated with differences between these variables.

Conclusions

Brain metastases from lung occur earlier, are more edematous, but fewer in number than those from breast cancers. Cerebellar brain metastases are more frequent in breast cancer.
Literatur
1.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRef Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRef
2.
Zurück zum Zitat Schouten LJ, Rutten J, Huveneers HA (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705PubMedCrossRef Schouten LJ, Rutten J, Huveneers HA (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705PubMedCrossRef
3.
Zurück zum Zitat Delattre JY, Krol G, Thaler HT (1988) Distribution of brain metastases. Arch Neurol 45:741–744PubMedCrossRef Delattre JY, Krol G, Thaler HT (1988) Distribution of brain metastases. Arch Neurol 45:741–744PubMedCrossRef
4.
Zurück zum Zitat Eichler AF, Kuter C, Ryan P et al (2008) Survival in patients with brain metastases from breast cancer. Cancer 112:2359–2367PubMedCrossRef Eichler AF, Kuter C, Ryan P et al (2008) Survival in patients with brain metastases from breast cancer. Cancer 112:2359–2367PubMedCrossRef
5.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC et al (eds) (2010) American Joint Committee on Cancer Staging Manual, 7th edn. Springer, Philadelphia Edge SB, Byrd DR, Compton CC et al (eds) (2010) American Joint Committee on Cancer Staging Manual, 7th edn. Springer, Philadelphia
6.
Zurück zum Zitat El-Tamer M, Hussain S, Weedon J et al (2002) Prognoses of T4 breast cancer subsets. Ann Surg Oncol 9:340–345PubMedCrossRef El-Tamer M, Hussain S, Weedon J et al (2002) Prognoses of T4 breast cancer subsets. Ann Surg Oncol 9:340–345PubMedCrossRef
7.
Zurück zum Zitat Yawn BP, Wollin PC, Schroeder C (2003) Temporal and gender-related trends in brain metastases from breast and lung cancer. Minn Med 86:32–37PubMed Yawn BP, Wollin PC, Schroeder C (2003) Temporal and gender-related trends in brain metastases from breast and lung cancer. Minn Med 86:32–37PubMed
8.
Zurück zum Zitat DiStefano A, Yap HY, Hortobabyi GN (1997) The natural history of breast cancer patients with brain metastases. Cancer 44:1913–1918CrossRef DiStefano A, Yap HY, Hortobabyi GN (1997) The natural history of breast cancer patients with brain metastases. Cancer 44:1913–1918CrossRef
9.
Zurück zum Zitat Fromm S, Bartsch R, Rudas M et al (2008) Factors influencing the time to development of brain metastases in breast cancer. Breast 17:512–516PubMedCrossRef Fromm S, Bartsch R, Rudas M et al (2008) Factors influencing the time to development of brain metastases in breast cancer. Breast 17:512–516PubMedCrossRef
10.
11.
Zurück zum Zitat Lu W, Bucana CD, Schroit AJ (2007) Pathogenesis and vascular integrity of breast cancer blood vessels. Int J Cancer 120:1023–1026PubMedCrossRef Lu W, Bucana CD, Schroit AJ (2007) Pathogenesis and vascular integrity of breast cancer blood vessels. Int J Cancer 120:1023–1026PubMedCrossRef
12.
Zurück zum Zitat Nathoo N, Chahlavi A, Barnett GH (2005) Pathobiology of brain metastases. J Clin Pathol 58:237–242PubMedCrossRef Nathoo N, Chahlavi A, Barnett GH (2005) Pathobiology of brain metastases. J Clin Pathol 58:237–242PubMedCrossRef
13.
Zurück zum Zitat Gerstner ER, Fine RL (2007) Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors. J Clin Oncol 25:2306–2312PubMedCrossRef Gerstner ER, Fine RL (2007) Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors. J Clin Oncol 25:2306–2312PubMedCrossRef
14.
Zurück zum Zitat Yokoi K, Kamiya N, Matsuguma H et al (1999) Detection of brain metastases in potentially operable non-small cell lung cancer. Chest 115:714–719PubMedCrossRef Yokoi K, Kamiya N, Matsuguma H et al (1999) Detection of brain metastases in potentially operable non-small cell lung cancer. Chest 115:714–719PubMedCrossRef
15.
Zurück zum Zitat Yoshida S, Takahashi H (2009) Cerebellar metastases in patients with cancer. Surg Neurol 71:184–187PubMedCrossRef Yoshida S, Takahashi H (2009) Cerebellar metastases in patients with cancer. Surg Neurol 71:184–187PubMedCrossRef
16.
Zurück zum Zitat Lee SS, Ahn JH, Kim MK et al (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523–530PubMedCrossRef Lee SS, Ahn JH, Kim MK et al (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523–530PubMedCrossRef
17.
Zurück zum Zitat Tham YL, Sexton K, Kramer R et al (2006) Primary breast cancer phenotypes associated with a propensity for central nervous system metastases. Cancer 107:696–704PubMedCrossRef Tham YL, Sexton K, Kramer R et al (2006) Primary breast cancer phenotypes associated with a propensity for central nervous system metastases. Cancer 107:696–704PubMedCrossRef
18.
Zurück zum Zitat Hinton CV, Avraham S, Avraham HK (2010) Role of the CXCR4/CXCL12 signaling axis in breast cancer metastases to the brain. Clin Exp Metastasis 27:97–105PubMedCrossRef Hinton CV, Avraham S, Avraham HK (2010) Role of the CXCR4/CXCL12 signaling axis in breast cancer metastases to the brain. Clin Exp Metastasis 27:97–105PubMedCrossRef
19.
Zurück zum Zitat Klein A, Olendrowitz C, Schmutzler R et al (2009) Identification of brain and bone specific breast cancer metastasis genes. Cancer Lett 276:212–220PubMedCrossRef Klein A, Olendrowitz C, Schmutzler R et al (2009) Identification of brain and bone specific breast cancer metastasis genes. Cancer Lett 276:212–220PubMedCrossRef
20.
Zurück zum Zitat Stark AM, Tongers K, Maass N et al (2005) Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 131:191–198PubMedCrossRef Stark AM, Tongers K, Maass N et al (2005) Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 131:191–198PubMedCrossRef
21.
Zurück zum Zitat Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. New Engl J Med 363:1938–1948PubMedCrossRef Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. New Engl J Med 363:1938–1948PubMedCrossRef
22.
Zurück zum Zitat Graesslin O, Abdulkarim BS, Coutant C et al (2010) Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28:2032–2037PubMedCrossRef Graesslin O, Abdulkarim BS, Coutant C et al (2010) Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28:2032–2037PubMedCrossRef
23.
Zurück zum Zitat Gore EM, Bae K, Wong SJ et al (2010) Phase III comparison of prophylactic cranial radiation in patients with locally advanced non-small cell lung cancer. J Clin Oncol 29:272–278PubMedCrossRef Gore EM, Bae K, Wong SJ et al (2010) Phase III comparison of prophylactic cranial radiation in patients with locally advanced non-small cell lung cancer. J Clin Oncol 29:272–278PubMedCrossRef
Metadaten
Titel
Attributes of brain metastases from breast and lung cancer
verfasst von
Kyle Hengel
Gurinder Sidhu
Jai Choi
Jeremy Weedon
Emmanuel Nwokedi
Constantine A. Axiotis
Xianyuan Song
Albert S. Braverman
Publikationsdatum
01.06.2013
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0392-x

Weitere Artikel der Ausgabe 3/2013

International Journal of Clinical Oncology 3/2013 Zur Ausgabe

Introduction to Review Articles

Old but new methods in radiation oncology

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.